Steps to Implementing Pharmacogenomics (PGx) in Your Practice
Warfarin, CYP2C9 and VKORC1
VL is a 62 yo Caucasian female who is now starting anticoagulation with warfarin for onset of atrial fibrillation. She is a Type 2 diabetic with hypertension and hyperlipidemia and is taking:
- Metformin 500 mg BID with meals
- Lisinopril 10 mg daily
- Atorvastatin 20 mg daily
VL does not smoke or drink and is advised to start a heart-healthy diet including increased salad intake. Her baseline INR is 1.0 with a goal of 2.5. Her genotype profile is:
- CYP2C9*3/*3
- VKORC1-1639A/A
Warfarin has a narrow therapeutic window with a significant risk of bleeding; PGx testing can be used to affect medication dosing. The CYP2C9 and VKORC1 polymorphisms can affect warfarin dosing. However, not all patients with polymorphisms in CYP2C9 or VKORC1 will have a serious bleeding event; those without any polymorphism may still be susceptible to having a bleeding event due to clinical, nongenetic factors.
The CYP2C9 alleles affect the metabolism of warfarin.
The VKORC1 1173 C>T or VKORC1-1639 G>A alleles affect the formation of vitamin K-dependent clotting factors.
Dosing Considerations:
- Patients with CYP2C9*2 or CYP2C9*3 alleles may have decreased CYP2C9 activities by 50% to 90%, requiring lower warfarin doses.
- Haplotype A from VKORC1 SNPs is associated with lower warfarin dose requirements; VKORC1A/A genotype generally requires a lower weekly warfarin dose of 32%.
- Haplotype B is associated with higher warfarin dose requirements; Haplotype B/B generally requires an increased weekly warfarin dose of 35%.
- It appears from numerous reports that the VKORC1 allele is of greater importance in determining the warfarin maintenance dose than is the CYP2C9 genotype.
Dosing data from a published table extracted and presented below may be of assistance:
VKORC1 Genotype | Cytochrome P450 CYP2C9 Genotypes *3/*3 |
A/A | 0.5 to 2 mg/d |
Next week, we will look at some resources available to support your PGx practice.
Loyd V. Allen, Jr., PhD, RPh
Editor-in-Chief
International Journal of Pharmaceutical Compounding
Remington: The Science and Practice of Pharmacy Twenty-second edition
|